CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation

Blood

Volumn 110, Issue 9, 2007, Pages 3447-3455

  Choi, Sung W ^a   Hildebrandt, Gerhard C ^a,b   Olkiewicz, Krystyna M ^a   Hanauer, David A ^c   Chaudhary, Meghana N ^a   Silva, Ines A ^a   Rogers, Clare E ^a   Deurloo, Daphne T ^a   Fisher, Jacki M ^a   Liu, Chen ^d   Adams, David ^c   Chensue, Stephen W ^a   Cooke, Kenneth R ^a,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR1; MESSENGER RNA; RANTES;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; EFFECTOR CELL; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOMODULATION; LIGAND BINDING; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SURVIVAL;

EID: 36148994331     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-087403     Document Type: Article

References (66)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-674.
2. Cooke KR, Hill GR, Gerbitz A, et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation. 2000;70:272-279.
3. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
4. Horowitz MM, Gale RP, Sondel PM, et al. Graft-verus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-561.
5. Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol. 2006;57:225-244.
6. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5:347-356.
7. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
8. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004;22:891-928.
9. Sallusto F. The role of chemokine receptors in primary, effector and memory immune response. Exp Dermatol. 2002;11:476-478.
10. Rollins BJ. Chemokines. Blood. 1997;90:909-928.
11. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436-445.
12. Youn BS, Mantel C, Broxmeyer HE. Chemokines, chemokine receptors and hematopoiesis. Immunol Rev. 2000;177:150-174.
13. D'Ambrosio D, Panina-Bordignon P, Sinigaglia F. Chemokine receptors in inflammation: an overview. J Immunol Methods. 2003;273:3-13.
14. Revesz L, Bollbuck B, Buhl T, et al. Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis. Bioorg Med Chem Lett. 2005;15:5160-5164.
15. Shahrara S, Proudfoot AE, Woods JM, et al. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum. 2005;52:1907-1919.
16. Anders HJ, Ninichuk V, Schlondorff D. Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int. 2006;69:29-32.
17. Ninichuk V, Anders HJ. Chemokine receptor CCR1: a new target for progressive kidney disease. Am J Nephrol. 2005;25:365-372.
18. Vielhauer V, Berning E, Eis V, et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int. 2004;66:2264-2278.
19. Ajuebor MN, Hogaboam CM, Le T, Proudfoot AE, Swain MG. CCL3/MIP-1alpha is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4(+) T cells to the liver. Eur J Immunol. 2004;34:2907-2918.
20. Yang X, Lu P, Fujii C, et al. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int J Cancer. 2006;118:1869-1876.
21. Reichel CA, Khandoga A, Anders HJ, Schlondorff D, Luckow B, Krombach F. Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue. J Leukoc Biol. 2006;79:114-122.
22. Bonville CA, Lau VK, DeLeon JM, et al. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J Virol. 2004;78:7984-7989.
23. Ness TL, Carpenter KJ, Ewing JL, Gerard CJ, Hogaboam CM, Kunkel SL. CCR1 and CC chemokine ligand 5 interactions exacerbate innate immune responses during sepsis. J Immunol. 2004;173:6938-6948.
24. Yun JJ, Whiting D, Fischbein MP, et al. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation. 2004;109:932-937.
25. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest. 2000;105:35-44.
26. Hildebrandt GC, Olkiewicz KM, Choi S, et al. Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. Blood. 2005;105:2249-2257.
27. Gerard C, Frossard JL, Bhatia M, et al. Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury. J Clin Invest. 1997;100:2022-2027.
28. Cooke K, Hill G, Crawford J, et al. Tumor necrosis factor-a production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft versus host disease. J Clin Invest. 1998;102:1882-1891.
29. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: the roles of minor H antigens and endotoxin. Blood. 1996;88:3230-3239.
30. Cooke KR, Krenger W, Hill G, et al. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood. 1998;92:2571-2580.
31. Duffner U, Lu B, Hildebrandt GC, et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol. 2003;31:897-902.
32. Teshima T, Hill GR, Pan L, et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest. 1999;104:317-325.
33. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581-1589.
34. Mack M, Cihak J, Simonis C, et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol. 2001;166:4697-4704.
35. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-1533.
36. Benvenuti F, Hugues S, Walmsley M, et al. Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming. Science. 2004;305:1150-1153.
37. Hill G, Krenger W, Ferrara J. Cytokine dysregulation in acute graft-versus-host disease. Hematology. 1998;2:423.
38. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003;21:149-161.
39. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol. 2003;78:181-187.
40. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754-2759.
41. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
42. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987-992.
43. Jaksch M, Remberger M, Mattsson J. Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:280-287.
44. Horuk R. Survey: chemokine receptors. Cytokine Growth Factor Rev. 2001;12:313-335.
45. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol. 2001;2:102-107.
46. Song A, Nikolcheva T, Krensky AM. Transcriptional regulation of RANTES expression in T lymphocytes. Immunol Rev. 2000;177:236-245.
47. Alam R, Stafford S, Forsythe P, et al. RANTES is a chemotactic and activating factor for human eosinophils. J Immunol. 1993;150:3442-3448.
48. Bischoff SC, Krieger M, Brunner T, et al. RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors. Eur J Immunol. 1993;23:761-767.
49. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990;347:669-671.
50. Koga S, Kapoor A, Novick AC, Toma H, Fairchild RL. RANTES is produced by CD8+ T cells during acute rejection of skin grafts. Transplant Proc. 2000;32:796-797.
51. Koga S, Novick AC, Toma H, Fairchild RL. CD8+ T cells produce RANTES during acute rejection of murine allogeneic skin grafts. Transplantation. 1999;67:854-864.
52. John AE, Berlin AA, Lukacs NW. Respiratory syncytial virus-induced CCL5/RANTES contributes to exacerbation of allergic airway inflammation. Eur J Immunol. 2003;33:1677-1685.
53. Sekine Y, Yasufuku K, Heidler KM, et al. Monocyte chemoattractant protein-1 and RANTES are chemotactic for graft infiltrating lymphocytes during acute lung allograft rejection. Am J Respir Cell Mol Biol. 2000;23:719-726.
54. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation. 2003;75:72-78.
55. Song E, Zou H, Yao Y, et al. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int. 2002;61:676-685.
56. Farivar AS, Krishnadasan B, Naidu BV, Woolley SM, Mulligan MS. The role of the beta chemokines in experimental obliterative bronchiolitis. Exp Mol Pathol. 2003;75:210-216.
57. Mulligan MS, McDuffie JE, Shanley TP, et al. Role of RANTES in experimental cardiac allograft rejection. Exp Mol Pathol. 2000;69:167-174.
58. Grone HJ, Weber C, Weber KS, et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J. 1999;13:1371-1383.
59. Suga M, Maclean AA, Keshavjee S, Fischer S, Moreira JM, Liu M. RANTES plays an important role in the evolution of allograft transplant-induced fibrous airway obliteration. Am J Respir Crit Care Med. 2000;162:1940-1948.
60. Belperio JA, Burdick MD, Keane MP, et al. The role of the CC chemokine, RANTES, in acute lung allograft rejection. J Immunol. 2000;165:461-472.
61. VanOtteren GM, Strieter RM, Kunkel SL, et al. Compartmentalized expression of RANTES in a murine model of endotoxemia. J Immunol. 1995;154:1900-1908.
62. Standiford TJ, Kunkel SL, Lukacs NW, et al. Macrophage inflammatory protein-1 alpha mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia. J Immunol. 1995;155:1515-1524.
63. Taub DD, Ortaldo JR, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol. 1996;59:81-89.
64. Makino Y, Cook DN, Smithies O, et al. Impaired T cell function in RANTES-deficient mice. Clin Immunol. 2002;102:302-309.
65. Proudfoot AE, Buser R, Borlat F, et al. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem. 1999;274:32478-32485.
66. Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AE, Wallace JL. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol. 2001;166:552-558.